دورية أكاديمية
أعرض في EDS

Ocular ketoconazole-loaded proniosomal gels: formulation, ex vivo corneal permeation and in vivo studies.

التفاصيل البيبلوغرافية
العنوان: Ocular ketoconazole-loaded proniosomal gels: formulation, ex vivo corneal permeation and in vivo studies.
المؤلفون: Abdelbary GA; a Department Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Cairo University , Cairo , Egypt and., Amin MM; a Department Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Cairo University , Cairo , Egypt and., Zakaria MY; b Department Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Sinai University , Sinai , Egypt.
المصدر: Drug delivery [Drug Deliv] 2017 Nov; Vol. 24 (1), pp. 309-319.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print Cited Medium: Internet ISSN: 1521-0464 (Electronic) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015->: Abingdon, Oxford : Taylor & Francis
Original Publication: Orlando, FL : Academic Press, c1993-
مواضيع طبية MeSH: Antifungal Agents/*metabolism , Cornea/*metabolism , Drug Carriers/*metabolism , Ketoconazole/*metabolism , Liposomes/*metabolism , Prodrugs/*metabolism, Animals ; Antifungal Agents/administration & dosage ; Cornea/drug effects ; Drug Carriers/administration & dosage ; Drug Liberation ; Gels ; Ketoconazole/administration & dosage ; Liposomes/administration & dosage ; Male ; Organ Culture Techniques ; Permeability/drug effects ; Prodrugs/administration & dosage ; Rabbits
مستخلص: Context: Vesicular drug carriers for ocular delivery have gained a real potential. Proniosomal gels as ocular drug carriers have been proven to be an effective way to improve bioavailability and patient compliance.
Objective: Formulation and in vitro/ex vivo/in vivo characterization of ketoconazole (KET)-loaded proniosomal gels for the treatment of ocular keratitis.
Materials and Methods: The effect of formulation variables; HLB value, type and concentration of non-ionic surfactants (Tweens, Spans, Brijs and Pluronics) with or without lecithin on the entrapment efficiency (EE%), vesicle size and in vitro KET release was evaluated. An ex vivo corneal permeation study to determine the level of KET in the external eye tissue of albino rabbits and an in vivo assessment of the level of KET in the aqueous humors were performed.
Results and Discussion: In vivo evaluation showed an increase in bioavailability up to 20-folds from the optimum KET proniosomal gel formula in the aqueous humor compared to drug suspension (KET-SP). The selected formulae were composed of spans being hydrophobic suggesting the potential use of a more hydrophobic surfactant as Span during the formulation of formulae. Factors that stabilize the vesicle membrane and increase the entrapment efficiency of KET (namely low HLB, long alkyl chain, high phase transition temperature) slowed down the release profile.
Conclusions: Proniosomal gels as drug delivery carriers were proven to be a promising approach to increase corneal contact and permeation as well as retention time in the eye resulting in a sustained action and enhanced bioavailability.
References: Int J Pharm. 2007 Jan 10;328(2):130-41. (PMID: 16997517)
Int J Pharm. 2002 Sep 5;244(1-2):73-80. (PMID: 12204566)
Int J Pharm. 2001 Oct 9;228(1-2):43-52. (PMID: 11576767)
Int J Pharm. 2008 Sep 1;361(1-2):104-11. (PMID: 18577437)
Int J Pharm. 2007 Aug 1;340(1-2):126-33. (PMID: 17600645)
Int J Pharm. 2005 Jul 14;298(1):55-67. (PMID: 15941634)
J Liposome Res. 2017 Jun;27(2):118-129. (PMID: 27079800)
Int J Pharm. 2000 Sep 25;206(1-2):110-22. (PMID: 11202988)
AAPS PharmSciTech. 2007 Jan 05;8(1):1. (PMID: 17408209)
Trends Biotechnol. 2000 Oct;18(10):412-20. (PMID: 10998507)
Int J Pharm. 2012 Jan 17;422(1-2):139-50. (PMID: 22079716)
Clin Exp Ophthalmol. 2000 Apr;28(2):113-7. (PMID: 10933774)
Int J Pharm. 2008 Mar 20;352(1-2):81-91. (PMID: 18061381)
Eur J Pharm Sci. 2014 Oct 1;62:115-23. (PMID: 24905830)
Expert Opin Drug Deliv. 2008 May;5(5):567-81. (PMID: 18491982)
J Pharm Pharmacol. 2004 Dec;56(12):1509-17. (PMID: 15563757)
Phys Rev Lett. 2004 Jul 9;93(2):028101. (PMID: 15323953)
J Ocul Pharmacol Ther. 2008 Oct;24(5):501-6. (PMID: 18803444)
Int J Pharm. 2008 Jun 5;357(1-2):189-98. (PMID: 18339494)
Drug Deliv. 2014 Jun;21(4):243-9. (PMID: 24128089)
AAPS PharmSciTech. 2008;9(3):740-7. (PMID: 18563578)
AAPS PharmSciTech. 2008;9(3):782-90. (PMID: 18587650)
J Ocul Pharmacol. 1986 Winter;2(1):67-108. (PMID: 3332284)
Int J Pharm. 2015 Nov 10;495(1):276-289. (PMID: 26325312)
Adv Drug Deliv Rev. 2004 May 7;56(9):1257-72. (PMID: 15109768)
Int J Pharm. 2001 Mar 14;215(1-2):101-11. (PMID: 11250096)
Eur J Pharm Biopharm. 2011 Jan;77(1):43-55. (PMID: 21056658)
Int J Pharm. 2004 Jan 9;269(1):1-14. (PMID: 14698571)
J Control Release. 1998 Jul 31;54(2):149-65. (PMID: 9724902)
Indian J Med Microbiol. 2006 Oct;24(4):273-9. (PMID: 17185846)
Int J Pharm. 2005 Dec 8;306(1-2):71-82. (PMID: 16263229)
Immunomethods. 1994 Jun;4(3):201-9. (PMID: 7820450)
Eur J Pharm Sci. 2005 Apr;24(5):411-9. (PMID: 15784331)
Int J Pharm. 2000 May 15;201(1):7-14. (PMID: 10867260)
فهرسة مساهمة: Keywords: Proniosomal gel; ex vivo corneal permeation; ketoconazole; ocular delivery; ocular keratitis
المشرفين على المادة: 0 (Antifungal Agents)
0 (Drug Carriers)
0 (Gels)
0 (Liposomes)
0 (Prodrugs)
R9400W927I (Ketoconazole)
تواريخ الأحداث: Date Created: 20170207 Date Completed: 20170606 Latest Revision: 20210709
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8241068
DOI: 10.1080/10717544.2016.1247928
PMID: 28165809
قاعدة البيانات: MEDLINE
الوصف
تدمد:1521-0464
DOI:10.1080/10717544.2016.1247928